Story Details
| Last Updated | |
| Total Articles | 2 |
Main Topics
single unit of ownership in a corporation, mutual fund, or any other organization
News on this topic
Eli Lilly stock surges as cheaper drugs unlock a bigger market : Lilly shares hit a record as weight-loss drugs became more accessible.
charlotteobserver.com/news/business/article317867373.html
Similar to This
Previous
Lilly says its obesity drugs helped patients lose weight in clinical trials: Eli Lilly & Co on Saturday released some new data from several clinical trials of ...
reuters.com/legal/litigation/lilly-says-its-obesity-drugs-helped-patients-lose-weight-clinical-trials-2026-11-14/
Eli Lilly beats Novo Nordisk to China approval for first oral GLP-1 weight-loss drug
thestar.com.my/aseanplus/aseanplus-news/2026/11/14/eli-lilly-beats-novo-nordisk-to-china-approval-for-first-oral-glp-1-weight-loss-drug
OpinionEli Lilly becomes first drugmaker to have a GLP-1 weight-loss pill approved in China
reuters.com/business/healthcare-pharmaceuticals/china-approves-eli-lillys-weight-loss-pill-orforglipron-2026-11-12/
Eli Lilly's obesity pill showed it can ease sleep apnea in a late-stage trial: Lilly plans to submit Foundayo to the FDA for moderate-to-severe sleep apnea in ...
qz.com/eli-lilly-foundayo-sleep-apnea-trial-fda-110926
STAT Nov 10
Paid articlePaywall Former Eli Lilly rep claims she was fired for complaining about marketing of Mounjaro diabetes drug
statnews.com/pharmalot/2026/11/10/former-lilly-rep-claims-she-was-fired-for-complaining-about-marketing-of-mounjaro-diabetes-drug/
Hims & Hers Surges On 'Surprising And Inevitable' Deal With Eli Lilly: Hims & Hers Health inked a deal with Eli Lilly on Friday to sell the company's ...
investors.com/news/technology/hims-stock-eli-lilly-branded-glp-1s-deal-zepbound-foundayo/
Higher sales of the Wegovy pill: Novo Nordisk raises forecast: The introduction of the Wegovy pill secures higher revenues for the Danish pharmaceutical company ...
faz.net/aktuell/wirtschaft/unternehmen/hoehere-verkaeufe-der-wegovy-pille-novo-nordisk-hebt-prognose-an-201650151.html
Novo Surges 5% After Walloping Expectations On The Back Of Its GLP-1 Drugs: Novo stock popped early Wednesday on better-than-expected third-quarter sales and ...
investors.com/news/technology/novo-stock-novo-earnings-q3-2026/
Paid articlePaywall Eli Lilly: Priced For Acceleration, Reporting Deceleration: Eli Lilly delivered strong Q3 results, but underlying growth slowed from 49% to 35% and price erosion ...
seekingalpha.com/article/4961727-eli-lilly-priced-for-acceleration-reporting-deceleration
Barron's Sep 22
Paid articlePaywall Viking Therapeutics Stock Surges 36%. It Could Challenge Lilly and Novo’s Obesity Empire.
barrons.com/articles/viking-therapeutics-stock-weight-loss-lilly-novo-bee2ded3
Novo CEO says obesity market won’t be winner-take-all battle with Lilly: Novo Nordisk CEO Mike Doustdar said investors are underestimating the demand for ...
bnnbloomberg.ca/business/company-news/2026/08/13/novo-ceo-says-obesity-market-wont-be-winner-take-all-battle-with-lilly/
Eli Lilly Q2 2026 earnings beat, raises full-year revenue forecast
dlvr.it/TTsjLD
GLP-1 drugs are driving higher sales for Eli Lilly and Novo Nordisk: Sales of Mounjaro, Eli Lilly’s diabetes drug, rose 91 per cent in the second quarter of the ...
globalnews.ca/news/12010271/glp-1-drugs-higher-sales-pharmaceutical/
Eli Lilly Just Launched Its $149 Obesity Pill - Eli Lilly (NYSE:LLY): Eli Lilly launches Foundayo weight-loss pill after FDA approval, priced from $149/month ...
benzinga.com/news/health-care/26/04/51735581/eli-lilly-just-launched-its-149-obesity-pill
Eli Lilly To Buy Centessa Pharma For Up To $7.8 Billion; Centessa Shares Skyrocket
investors.com/news/technology/eli-lilly-centessa-pharmaceuticals-acquisition-narcolepsy-insomnia/
Novo Nordisk hopes to see US Wegovy sales recover soon: Drugmaker Novo Nordisk expects Wegovy weight-loss drug sales in the United States to start to recover ...
reuters.com/business/healthcare-pharmaceuticals/obesity-drugmaker-novo-nordisk-cuts-2025-outlook-posts-q1-profit-above-forecast-2025-05-07/
Key FactsNovo Nordisk Optimistic Despite Sales Forecast Cuts
May 7, 2025 · Reading time: ~45 sec.
Summary created with AI assistance · Source: reuters.com
Summary created with AI assistance · Source: reuters.com
- Novo Nordisk anticipates a recovery in Wegovy sales in the U.S. following the FDA's ban on compound copycats.
- Sales forecasts for 2025 have been lowered due to market impact from compounding pharmacies.
- Novo recently launched Wegovy in three additional countries and plans to accelerate further launches.
- Quarterly profits exceeded analyst expectations while shares rose by 4%.
It's unprecedented in our industry to have very large volumes of products flowing to patients that are not approved.— Lars Fruergaard Jorgensen, CEO of Novo Nordisk, discussing the impact of unapproved medications on the company's growth.
Wegovy price cut: Novo Nordisk cuts the price of the weight-loss drug for the uninsured
usatoday.com/story/money/business/2025/03/05/weight-loss-drug-wegovy-price-cut/81613259007/
Next